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This study was designed to identify specific gene expression changes in tongue squamous cell carcinomas (TSCCs) compared with
normal tissues using in-house cDNA microarray that comprised of 2304 full-length cDNAs from a cDNA library prepared from
normal oral tissues, primary oral cancers, and oral cancer cell lines. The genes identified by our microarray system were further
analysed at the mRNA or protein expression level in a series of clinical samples by real-time quantitative reverse transcriptase–
polymerase chain reaction (qRT–PCR) analysis and imuunohositochemistry. The microarray analysis identified a total of 16 genes that
were significantly upregulated in common among four TSCC specimens. Consistent with the results of the microarray, increased
mRNA levels of selected genes with known molecular functions were found in the four TSCCs. Among genes identified, Rab1a,a
member of the Ras oncogene family, was further analysed for its protein expression in 54 TSCCs and 13 premalignant lesions. We
found a high prevalence of Rab1A-overexpression not only in TSCCs (98%) but also in premalignant lesions (93%). Thus, our results
suggest that rapid characterisation of the target gene(s) for TSCCs can be accomplished using our in-house cDNA microarray analysis
combined with the qRT–PCR and immunohistochemistry, and that the Rab1A is a potential biomarker of tongue carcinogenesis.
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Squamous cell carcinoma (SCC) is by far the most common
malignant neoplasm of the oral cavity, representing approximately
90% of all oral cancers. Although it occurs at various oral regions,
the tongue is one of the most frequent sites (Boyle et al, 1992;
Perkin et al, 1993). A number of aetiologic factors have been
implicated in the development of oral SCCs, such as the use of
tobacco, alcohol, or the presence of incompatible prosthetic
materials (Mashberg et al, 1993; Macfarlane et al, 1995). However,
some patients without those risk factors actually develop tumours
of the tongue, and there are individual variations in the
progression or differentiation of the cancer, which suggests that
host susceptibility may play a role. In this context, molecular
alterations in a number of oncogenes and tumour suppressor
genes associated with the development of tongue SCC (TSCC)
could be important clues for addressing these problems (Fearon
and Vogelstein, 1990; Marshall, 1991).
Recent reports have documented alterations of a few oncogenes
and tumour suppressor genes in oral cancer including TSCC
(Scully et al, 2000), but the molecular and genetic basis of tongue
carcinogenesis still remains largely unknown and global gene
expression has not been clarified. In recent years, the cDNA
microarray system has facilitated the simultaneous investigation of
a large set of genes or gene clusters, allowing analysis of even
complex processes in a short time (Schena et al, 1995; DeRisi et al,
1996). We recently developed an in-house cDNA microarray
derived from our oligo-capped human oral cancer cDNA library
(Moriya et al, 2003). This microarray system successfully identified
genes that are differentially expressed in common in oral SCC-
derived cell lines compared with those in normal oral tissues,
indicating that this system may be a powerful prioritisation tool in
the search for disease significance.
In the present study, we attempted to identify target gene(s) for
TSCC using our cDNA microarray. In addition, expression states
of the mRNA and protein of candidate genes were evaluated
further by real-time quantitative reverse transcriptase–polymerase
chain reaction (qRT–PCR) analysis, or both and semiquantitative
immunohistochemistry in a large series of tumours of the tongue
and premalignant lesions of the tongue (tongue leukoplakias:
TLPs).
MATERIALS AND METHODS
Tissue samples
Tumours of the tongue or premalignant lesions of the tongue
(histologically diagnosed as TLPs), with patient-matched normal
epithelium where available, were obtained at the time of surgical
resection at Chiba University Hospital after the patient’s informed
consent was obtained under a protocol reviewed and approved by
the institutional review board of Chiba University. The resected
tissues were divided into two parts, one of which was frozen
immediately after careful removal of the surrounding normal
tissues and stored at  801C until RNA isolation; the second part
was fixed in 10% buffered formaldehyde solution for pathologic
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sdiagnosis and for immunohistochemical staining. Histopathologic
diagnosis of each neoplastic tissue was performed according to the
World Health Organisation criteria by the Department of
Pathology, Chiba University Hospital. Clinicopathologic staging
was determined by the TNM classification of the International
Union against Cancer. All patients had SCC or leukoplakia that was
histologically confirmed, and tumour samples were checked to
ensure that tumour tissue was present in more than 80% of the
specimens.
RNA isolation
Total RNA was extracted using Trizol Reagent (Invitrogen Life
Technologies, Carlsbad, CA, USA) according to the manufacturer’s
instructions. Each of extracted RNA was stored separately at
 801C until use.
In-house cDNA microarray analysis
In total, 20mg of purified total RNA obtained from four randomly
selected patients with TSCC was subjected to microarray analysis.
Samples of total RNA from these patients were similarly purified
and pooled to serve as controls. A cDNA microarray chip
consisting of 2304 cDNAs was created as previously described
(Moriya et al, 2003). The cDNA microarray was based on an oligo-
capped cDNA library of the OSCC tissues, oral normal tissues and
OSCC-derived cell lines: unique clones (2304) were selected from
about 4608 sequenced clones in the library. cDNA microarray
analysis was performed as described previously (Yoshikawa et al,
2000). Briefly, Cy3-dUTP or Cy5-dUTP (Amersham Biosciences
UK Ltd, UK) was incorporated during reverse transcription of
20mg of purified total RNA, primed by an oligo dT primer.
Different fluorescent-labelled probes from each tumour and
normal tissues were mixed and applied to the cDNA microarray
after incubation at 651C overnight in a humidified atmosphere.
Two hybridyzations were carried out for each experiments in
which the fluorescent dyes were switched during cDNA synthesis.
Each pair of corresponding probes was hybridysed to a separate
microarray. The fluorescent images of hybridised microarrays
were scanned with a fluorescence laser confocal slide scanner
(Scan Array Lite, Packard Bio Science, Billerica, MA, USA). Images
were analysed with microarray analysis software (QuantArray,
Packard Bio Science), according to the manufacturer’s instruc-
tions. Spots were only included if their raw fluorescence intensities
at least 1.5 times the local background.
Real-time quantitative RT–PCR
qRT–PCR was used to examine the expression status of the 10
genes whose function is known.
The cDNA templates for qRT–PCR were synthesised from the
four RNA samples of TSCCs used in the microarray analysis, and
two additional RNA samples were prepared for the evaluation of
Rab1a gene expression. The nucleotide sequences of gene-specific
primers and predicted sizes of the resulting PCR products for
qRT–PCR are shown in Table 1. qRT–PCR was performed with a
single method using a LightCycler FastStart DNA Master SYBR
Green I kit (Roche Diagnostics GmbH, Mannheim, Germany). For
preparing the standard curve, 1.5mg of total RNA from normal
oral tissue was reverse transcribed with Superscriptt reverse
transcriptase (Life Technologies, Grand Island, NY, USA) and
oligo-d(T)12 18 primer, after which serial dilutions were made
corresponding to cDNA transcribed from 300, 30, 3.0, and 0.3ng of
total RNA. The PCR reactions using a LightCycler (Roche)
apparatus were carried out in a final volume of 20ml of reaction
mixture consisting of 2ml of FirstStart DNA Master SYBR Green I
mix (Roche), 3mM MgCl2, and 0.2ml of the primers, according to
the manufacturer’s instructions. The reaction was performed as
per the manufacturer’s instructions. The transcript amount for
genes were estimated from the respective standard curves and
normalised to the glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) transcript amount determined in corresponding
samples.
Immunohistochemistry
Out of the differentially upregulated genes, one gene (Rab1a) was
singled out as a valid candidate biomarker of TSCC. In totl, 54
pairs of tongue carcinoma and matched normal tissue and 13 TLP
paraffin-embedded tissue samples were used for immunohisto-
chemistry to examine Rab1A protein expression status. Sections
(4mm) were deparaffinised, unmasked Rab1A antigen by micro-
wave treatment in 10mM sodium citrate buffer (pH6) and rinsed
three times in PBS solution. After quenching the endogenous
peroxidase activity in 0.5% H2O2 for 30min, the sections
were reacted with Rab1A polyclonal antibody (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) at a dilution of 1:50
overnight at room temperature in a humidified atmosphere. Upon
incubation with the primary antibody, the specimens were washed
three times in phosphate-buffered saline and treated with
ENVISION reagent (DAKO JAPAN Inc., Kyoto, Japan) followed
by colour development in 3,30-diaminobenzidine tetrahydrochlor-
ide (DAKO). Finally, the slides were lightly counterstained with
haematoxylin, dehydrated with ethanol, cleaned with xylene, and
mounted. As a negative control, duplicate sections were immu-
nostained without exposure to primary antibodies. To quantitate
the state of Rab1A protein expression, the mean percentage of
positive tumour cells was determined in at least five random fields
at  400 magnification in each section. The intensity of the
Table 1 Primer pairs for quantitative RT–PCR analysis
Gene
a Forward primer Reverse primer
IGHM 50-TCAGTAGACAGCTCCAAGACCAG-30 50-CCCAGACGTCCATACCGTAGTAGTAGT-30
SPON1 50-CTCTTCCTGCAGAGGAGTAGTGTCA-30 50-CTGGGACTCAGGCATAGTCACTTC-30
PKM2 50-GGAATGAATGTGGCTCGTCTG-30 50-CCAGCGTGATTTTGAGAGTGG-T-30
IGKC 5-AGCCTTGATCCTTGGGAATC-30 50-GAAAGCCCTGAGGCTTCTCT-30
P4HB 5-ACAGCTTCCCCACACTCAG-30 50-GGGTCTGGCTTTGCGTATTA-30
CALR 5-GTTTCGAGCCTTTCAGCAC-30 50-GAAGTCCCAATCGTCTTCCA-30
CAPZB 50-TGGAGGTGGAAGCCAACAAT-30 50-CGCTGGATTTCTCCTGCACT-30
Rabla 50-TATGGGACACAGCAGGCCAGG-30 50-ACGGAATTCCAAGGGAATCAGC-30
RALBP1 50-CTGGTGGACTCCCAATTGAC-30 50-GTGTGGGGTTTGTTTTCGAC-30
SERPINF 50-GCTGTCTCCAACTTCGGCTA-30 50-GTAGAGAGCCCGGTGAATGA-30
GAPDH 50-CATCTCTGCCCCCTCTGCTGA-30 50-GGATGACCTTGCCCACAGCCT-30
aIGHM¼immunoglobulin heavy constant mu; SPON1¼spondin 1; PKM2¼pyruvate kinase muscle type 2; IGKC¼immunoglobulin kappa constant region; P4HB¼procolla-
gen-proline,2-oxoglutarate-4-dioxygenase,beta; CALR¼calreticulin; CAPZB¼capping protein muscle Z-line, beta; RALBP1¼rala-binding protein 1; SERPINF¼pigment
epithelium-derived factor.
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sRab1A-immunoreaction was scored as follows: 1þ, weak; 2þ,
moderate; and 3þ, intense. The percentage of positive tumour
cells and the staining intensity then were multiplied to produce a
Rab1A-immunohistochemical staining score. Cases with a Rab1A
score 476.17 (the highest score of normal tissue) were defined as
positive. These judgments were made by two independent
pathologists, neither of whom had any knowledge or information
pertaining to the patients’ clinical status. Any discrepancy in the
scoring of the slides was resolved jointly by the pathologists by
discussion and a consensus observation was recorded afterward.
Statistical significance was evaluated by the Fisher’s exact test, or
Mann–Whitney’s U-test.
RESULTS
Identification of candidate TSCC target genes
In the search for genes involved in the development of human
TSCC, we compared gene expression between tumorous and
normal tongue tissue samples in four patients with TSCC. The
comparison between tumours and normal tissues showed that 16
genes were upregulated in all cases (Table 2).
Validation of the in-house cDNA microarray results
To further validate the cDNA array approach, we performed qRT–
PCR on the 10 genes with known function (Table 1) to analyse
mRNA expression level in the four TSCC cases examined by the
cDNA microarray analysis. We found that all the 10 genes showed
a significant upreguration in tumour tissues (Figure 1A, B) when
compared to corresponding normal tissues, although the fold
change in the expression level was not exactly same between the
microarray analysis and qRT–PCR. In addition, there was a
statistically significant difference of the Rab1a gene expression
status between TSCCs (n¼6) and matched normal tongue tissues
(Wilcoxon signed-rank test, P¼0.0277; Figure 1B). Futhermore, all
the TSCCs showing upregulation of the Rab1a mRNA expression
revealed overexpression of the protein.
Expression of Rab1A in malignant and premalignant
lesions of the tongue
In total, 54 patients with TSCC were identified for whom there was
adequate histologic material available for immunohistochemical
analysis. The correlation between the clinicopathologic character-
istics of patients with TSCC and Rab1A expression status is
summarised in Table 3. All normal oral mucosa specimens had no
or significant downregulation of Rab1A expression and were
considered as Rab1A-negative (Fisher’s exact test). Among the
tumours examined, 53 of 54 cases (98%) had a Rab1A-
immunoreaction in the cytoplasm of the tumour cells (Table 3).
However, there was no statistically significant differences between
Rab1A expression and the clinicopathologic features (Table 3).
Interestingly, 12 of 13 TLPs (93%) were considered Rab1A-
positive. Representative results for Rab1A protein expression in
normal oral tissue, TLP, and primary TSCC are shown in Figure 2.
The Rab1A immunohistochemistry scores for normal tissues,
TLPs, and TSCCs ranged from 0 to 76.2 (mean, 31.9), 73.5 to 182.9
(mean, 121.4), and 60.2 to 221.8 (mean, 148.0), respectively. The
Rab1A expression levels in primary TSCCs and TLPs were
significantly higher than those in normal oral tissues (Mann–
Whitney’s U-test, Po0.0001; Figure 3). There was also a significant
difference in RAB1A-IHC scores between TSCCs and TLPs
(Mann–Whitney’s U-test, P¼0.0298; Figure 3).
DISCUSSION
Considerable evidence has been reported that the identification of
novel disease relevant targets/pathways and tumour classification/
stratification can be achieved by microarray-based gene expression
profiling. In this context, there are numerous studies of the use of
disease profiles in tumours of clinically relevant subgroups,
including the brain (Sallinen et al, 2000), oesophagus (Lu et al,
2001), lung (Wang et al, 2000), gastrointestinal tract (El-Rifai et al,
2001; Inoue et al, 2002), thyroid (Wasenius et al, 2003), breast
(Assersohn et al, 2002; Ellis et al, 2002), leukaemia (Moos et al,
2002), colon (Williams et al, 2003), prostate (Bull et al, 2001).
There are also several studies to classify OSCCs using commer-
cially available cDNA microarrays (Ohyama et al, 2000; Alevizos
et al, 2001; Kuo et al, 2002; Vigneswaran et al, 2005). We recently
developed an in-house cDNA microarray derived from our oligo-
capped human cDNA library prepared from noncancerous and
cancerous tongue tissues, and oral cancer cell lines (Moriya et al,
2003).
The first step in the present study was to identify gene(s) that
were differentially expressed in TSCC compared with normal
tongue epithelium using the in-house cDNA microarray system.
Defining a 2.0-fold difference as the threshold, 16 genes of interest
were identified from four TSCC specimens. As shown in Table 2,
13 were known genes and three were unknown genes. In total, 10
genes (IGHM, SPON1, PKM2, IGKG, P4HB, CALR, CAPZB,
RALBP1, SERPINF1, and Rab1a) with known molecular function
Table 2 Genes with high expression levels in TSCCs
UniGene ID Gene Molecular function Chromosomal position Fold change
a
Hs.297962 Hypothetical protein Unknown Chromosomes 19 10.79
Hs.153261 1GHM Immune system 14q32.33 9.02
Hs.5387 SPON1 Extracellular matrix protein Ilpl4–pl5.2 5.92
Hs.198281 PKM2 Catalyse the production of phosphoenolpyruvate 15q22 5.66
Hs.406565 1GKC Immune system 2pl2 5.25
Hs.90315 KIAA0007 Unknown 2p23.2 4.61
Hs.55098 C3orf6 Unknown Chromosomes 3 3.24
Hs.43431 Hypothetical protein Unknown 6p22.3 2.92
gb|BX442293
b Unknown Unknown Unknown 2.82
Hs.83286 Hypothetical protein MGC33424 Unknown Unknown 2.61
Hs.410578 P4HB Protein disulphide isomerase 17q25 2.57
Hs.353170 CALR Calciumstrage, transcriptin co-repressor 19pl3.3–pl3.2 2.57
Hs.333417 CAPZB Actin binding lpG6.1 2.45
Hs.227327 Rabla(RAS oncogene family) RAB small monomeric GTP ase 2pl4 2.27
Hs.75447 RALBP1 GTPase activator Ispll.3 2.22
Hs.173594 3ERP1NF1 Serine protease inhibitor 17pl3.1 2.16
aFold over-expression for rnicroarray data based on ratio of fluorescence for TSCCs compared to normal control.
bGenBank Accession Number.
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swere subjected to qRT–PCR analysis, and they were confirmed to
be upregulated in the TSCCs examined, when compared to the
corresponding normal tissues. So far, none of these genes or their
corresponding proteins have been attributed directly to the
development of TSCC, suggesting that these genes are novel
potential targets for this disease.
Immunoglobulin heavy constant mu (IGHM) encodes the heavy
chain unique to IgM that is on chromosome 14q32.33. Chromo-
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Figure 1 Validation of cDNA microarray data by real-time quantitative RT–PCR (qRT–PCR). (A) Nine genes with known molecular function were
subjected to qRT–PCR in the mRNA from four TSCCs and four samples of the corresponding normal tissue used in the microarray analysis. A significant
upregulation was evident in all the genes evaluated. (B) A significant higher expression of the Rab1a gene was detected in primary TSCCs (n¼6) than that
in the six corresponding normal tissues (P¼0.0277, Wilcoxon signed-rank test). Relative expression ratio is defined as the expression levels of the gene to
those of the internal reference gene, GAPDH. The assays were carried out in triplicate and means7standard deviations were plotted.
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ssome rearrangements of this band affect the AKT1 gene, the proto-
oncogene of the viral oncogene v-akt (Staal et al, 1988).
Spondin 1 (SPON1) is an extracellular matrix protein. Nagase
screened human brain cDNAs for the potential to encode proteins
that are at least 50kDa, which they called KIAA0762 (Nagase et al,
1998). It is similar to rat F-spondin; thus, this gene may have a role
in the growth and guidance of axons. They also indicated that the
SPON1 gene is on chromosome 11p15.2. Nearby are the MUC2 and
MUC6 genes (11p15) that might be related to lymph node
metastasis (Nishiumi et al, 2003).
Pyruvate kinase muscle type 2 (PKM2) is known as ATP:pyr-
uvate phosphotransferase and occurs in four isozymic forms (L, R,
M1, M2). Tsutsumi et al (1988) isolated and sequenced two
overlapping clones covering the entire coding sequence of PKM2.
Kress et al (1998) indicated that mRNA level of PKM2 is increased
in human colorectal cancers in comparison to the corresponding
normal tissues.
IGKG encode immunoglobulin kappa chain constant region.
Lenormand et al (1991) reported 20 of the 25 patients with B-cell
chronic lymphocytic leukaemia (B-CELL) showed IGKC rearrange-
ment.
P4HB is involved in hydroxylation of prolyl residues in
preprocollagen. Tasanen et al (1988) isolated genomic clones for
the human gene coding for this multifunctional protein. Pajunen
et al (1987, 1988) assigned the gene to chromosome 17, specifically,
17q23–q25. The chromosomal aberration of this region may be
involved in carcinogenesis in the tylosis with oesophageal cancer
(TOC) (Shahabi et al, 2004) and liver cancer (Midorikawa et al,
2004).
CALR is a multifunctional protein that acts as a major Ca(2þ)-
binding (storage) protein in the lumen of the endoplasmic
reticulum. Accumulation of CALR protein is observed in a few
cancers, including breast cancer (Franzen et al, 1996) and
hepatocellular carcinoma (Yoon et al, 2000).
Capping protein muscle Z-line, beta (CAPZB) is a member of the
F-actin capping protein family. Barron-Casella et al (1995) isolated
cDNAs homologues for the beta subunit of chicken Cap Z from
human retinal cDNA libraries. This gene encodes the beta subunit
of the barbed-end actin binding protein that regulates growth of
the actin filament by capping the barbed end of growing actin
filaments. Those investigators mapped the CAPZB gene to 1p36.1,
which has frequent loss of heterozygosity observed in neuroblas-
tomas (Fong et al, 1989) and in oropharyngeal epithelial
carcinomas (Grati et al, 2000).
Table 3 Correlation between Rabla expression and clinicopathologic
features in human oral cancer
Clinical classification
Result of immunostaining
(no. of patients, %)
Total RablA(+) RablA( ) P-value
Age at surgery
o60 27 27 (100) 0 (0) 0.24074
60–70 14 14 (100) 0 (0)
X70 13 12 (92) 1 (8)
Gender
Male 35 34 (97) 1 (3) 1
Female 19 19 (100) 0 (0)
T of primary tumor
Tl 6 6 (100) 0 (0) 0.33333
T2 18 18 (100) 0 (0)
T3 18 18 (100) 0 (0)
T4 12 11 (92) 1 (8)
N of regional lymph node
K (+) 40 39 (98) 1 (2) 1
K(  ) 14 14 (100) 0 (0)
Stage
I 5 5 (100) 0 (0) 1
II 5 5 (100) 0 (0)
III 16 16 (100) 0 (0)
IV 28 27 (96) 1 (4)
Histopathological type
Well differentiated 35 34 (97) 1 (3) 1
Moderately differentiated 9 9 (100) 0 (0)
Poorly differentiated 10 10 (100) 0 (0)
Leukoplakias 13 12 (92) 1 (8)
Figure 2 Immunohistochemical staining of Rab1A. (A) Normal tongue
epithelium tissue shows weak expression of Rab1A protein. (B) Rab1A-
positive case of TLP. The immunoreaction is slightly enhanced in the basal
layer. (C) TSCC tissue shows strong cytoplasmic staining of the tumour
cells. Original magnification,  40. Bar¼100mm.
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which they termed RLIP76. RALBP1 participate in signalling for a
variety of cellular processes and are regulated in part by guanine
nucleotide dissociation stimulators, and coordinate the cellular
actions of activated EGF receptors and Ral-GTPases. The activity
of RALBP1 may contribute to the drug-resistant of small-cell lung
cancer (SCLC) (Singhal et al, 2003).
Serpins are a group of serine protease inhibitors, some of which
have also been reported to exhibit neurotrophic activity. In studies
aimed at identifying antiangiogenic factors in the eye, Dawson et al
(1999) identified SERPINF1. SERPINF1 may serve as a multi-
functional antitumour agent in neuroblastomas, inhibiting angio-
genesis (Crawford et al, 2001).
Rab1a is a member of the Ras oncogene superfamily. Rab
proteins represent a family of at least 30 different Ras-like GTPases
that function in the processes by which membrane vesicles identify
and/or fuse with their targets (Zahraoui et al, 1989; Ferro-Novick
and Novick, 1993; Novick and Brennwald, 1993; Jaakko et al,
1995), suggesting that abnormal regulation of membrane traffic,
which is one of the important cellular processes, may lead to
tumorigenesis. Thus, we have selected the Rab1a gene for further
investigation. To clarify its relative contribution to tongue
carcinogenesis, we further investigated the protein expression in
a series of TSCCs and TLPs. We detected a comparatively strong
tumour cell-localised cytoplasmic Rab1A-immunoreaction, raising
the possibility that the gene product(s) may serve as a diagnostic
marker of tongue cancer. By evaluating the Rab1A immunohis-
tochemistry scores using the Mann–Whitney’s U-test, significant
Rab1A upregulation was evident not only in the primary TSCCs
(Po0.0001, TSCC vs corresponding normal tissues) but also in the
TLPs (Po0.0001, TLPs vs corresponding normal tissues) when
compared with normal tissues. In addition, the levels of Rab1A
expression in SCCs tended to be higher than that in TLPs
(P¼0.0268), suggesting that Rab1A expression is not only a
precipitous event during tongue carcinogenesis but also an
important candidate for the progression of TSCCs. In addition,
whereas most corresponding normal tongue squamous cells
appeared not to express Rab1A, faint but positive cytoplasmic
staining was detected in a basal layer of tongue epithelial cells of
matched normal tongue tissue (Figure 2A). One possible explana-
tion is that Rab1A could be associated with proliferation state
(even of normal epithelium). Thus, it might be a secondary event
not directly associated with cancer causes. At present, it is unclear
why basal layer of normal epithelium showed Rab1A protein
stimulation. Further studies on a large series of patients and in
samples of a proliferative, noncancererous disorder, will provide
more accurate information about the involvement of Rab1A
expression in the development of TSCC.
Overall, we found expression profile changes that suggest
genetic alterations not only favouring a transformed epithelial cell
per se but also having the capabilities of modulating the immediate
microenvironment, which may aid tumour progression in the
tongue. The present study identified aberrant Rab1A expression in
premalignant and malignant tissues, suggesting its appearance and
overexpression in TLPs as a possible biologic marker of imminent
progression. The association of genes identified in our study with
clinical variables and gaining an understanding of the regulation of
their expression will aid in determining their potential use as
molecular markers in this cancer.
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